%0 Journal Article %A Jorge Levican %A Leonardo I. Almonacid %A Gonzalo Valenzuela %A Tamara García-Salum %A Luis Rojas %A Eileen Serrano %A Catalina Pardo-Roa %A Erick Salinas %A María José Avendaño %A Fabiola Perazzo %A Luis Antonio Díaz %A Sebastián Valderrama %A Marcos Ortega %A Adriana Toro %A Viviana Montecinos %A Arnoldo Riquelme %A Rafael A. Medina %T Viral shedding dynamics reveals sputum as a reliable and cost-saving specimen for SARS-CoV-2 diagnosis within the first 10 days since symptom onset: A prospective cohort study %D 2020 %R 10.1101/2020.08.30.20183889 %J medRxiv %P 2020.08.30.20183889 %X Background Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome virus (SARS-CoV-2) is challenging global public health, due to an increasing demand for testing and the shortage of diagnostic supplies. Nasopharyngeal swab (NPS) is considered the optimal sample for SARS-CoV2 diagnosis and sputum (SPT) has been proposed as an economic alternative. However, the temporal concordance of diagnosis in NPS and SPT has not been addressed.Methods Through a longitudinal study we compared the shedding dynamics of SARS-CoV-2 RNA evaluated by RT-qPCR in serially collected SPT and NPS obtained from 82 ambulatory and hospitalized patients during acute infection and convalescence. The concordance during the follow-up and cost analysis between both collected specimens was evaluated.Findings We analyzed 379 samples, 177 NPS and 202 SPT. The highest proportion of positive samples was detected within the first 15 days after the symptoms onset. The median time of positivity was higher for NPS (median= 25 days) than SPT (median= 21 days). There was no significant difference in the median RT-qPCR CT values between both sample types. The temporal categorization of matched-paired samples indicated substantial correlation (r=0·6023) and substantial agreement (87·23%) during the first ten days since symptoms onset (kappa = 0·697). A cost analysis demonstrated a significant saving when the SPT specimen was used.Interpretation Sputum is a feasible and cost-saving alternative to NPS, providing an equivalent value for the detection and follow-up of SARS-CoV-2 RNA.Funding Agencia Nacional de Investigación y Desarrollo (ANID) of Chile, NIH-NIAID USA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementProtocols and the study set-up used for this study were based on influenza virus studies established in part with the support of the FONDECYT 1161971 and ACT 1408 grants from the Agencia Nacional de Investigacion y Desarrollo (ANID) from Chile, the FLUOMICS Consortium (NIAID grant U19AI135972) funded by NIH and with funding from CRIP (Center for Research on Influenza Pathogenesis), an NIH funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract number HHSN272201400008C) to RAM.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained under protocol 16-066, which was reviewed and approved by the Scientific Ethics Committee at Pontificia Universidad Catolica de Chile (PUC)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in this manuscript are available to other researchers upon request to the corresponding researcher, email: rmedinai{at}uc.cl %U https://www.medrxiv.org/content/medrxiv/early/2020/09/01/2020.08.30.20183889.full.pdf